lixivaptan
Phase 3- Indications
- Heart failure, Hyponatremia, Liver cirrhosis, Syndrome of inappropriate antidiuretic hormone secretion
Company intelligence / Profile preview
CardioKine
Philadelphia, Pennsylvania, United Statesftc.gov ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
CardioKine developed lixivaptan, an orally active selective vasopressin V2 receptor antagonist for treating hyponatremia. The company completed multiple Phase III clinical trials demonstrating efficacy and safety in patients with chronic hyponatremia due to heart failure or SIADH. A New Drug Application was filed with the FDA at the end of December 2011. The company was acquired by Cornerstone Therapeutics shortly thereafter.
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Small molecules (notably oral compounds)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Biogen Idec – co-development agreement for lixivaptan prior to acquisitionWyeth/Pfizer – original licensor of lixivaptan compound to CardioKineCornerstone Therapeutics – acquirer and commercial partner post-acquisition
Beyond the preview
Go deeper on CardioKine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CardioKine.